Amphastar Pharmaceuticals Inc Stock News

RANCHO CUCAMONGA, CA / ACCESS Newswire / April 3, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating in an Analyst-Moderated fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9th, 2025, at 1:30 pm ET. For access, visit Amphastar's Pharmaceuticals w...

Recognized for contributions to address shortage of epinephrine injection, 0.1 mg/mL syringes RANCHO CUCAMONGA, CA / ACCESS Newswire / March 28, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that International Medication Systems, Ltd. ("IMS"), a subsidiary of Amphastar Pharmaceuticals, Inc. ("Amphastar") received a Drug Shortage Assistance Award from the U.S. Food and Dru...

RANCHO CUCAMONGA, CA / ACCESS Newswire / March 5, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations will be presenting at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12th, 2025, at 10:30 am ET. For access, visit Amphastar's Pharmaceuticals website at http://ir...

Amphastar Pharmaceuticals posted modest earnings growth but fell short of market expectations in its latest quarterly results.

Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Dan Dischner - Senior Vice President of Corporate Communications William Peters - Chief Financial Officer & Executive Vice President of Finance Tony Marrs - Executive Vice President of Regulatory Affairs & Clinical Operations Conference Call Participants Jason Gerberr...

Reports Net Revenues of $186.5 Million for the Three Months Ended December 31, 2024 RANCHO CUCAMONGA, CA / ACCESS Newswire / February 27, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months and full year ended December 31, 2024. Fourth quarter Highlights Net revenues of $186.5 million for the fourth quarter GAAP net inc...

RANCHO CUCAMONGA, CA / ACCESS Newswire / February 20, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its Fourth quarter of 2024 ended December 31, 2024, after the market closes on Thursday, February 27, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.

Amphastar Pharmaceuticals has a growth model based on organic growth and acquisitions, though competition and patent expirations pose risks. Financially, Amphastar has a strong revenue trend but faces potential growth slowdowns, especially in 2025. A fair value estimate derived from a DCF model and backed by a comparison with peers is $43.24, which suggests a 40% upside.